税金及附加 26,816,307.83 29,528,550.80 销售费用 620,586,202.68 638,226,395.90 管理费用 180,754,339.09 173,744,849.65 研发费用 118,627,834.42 114,594,982.81 财务费用 14,555,119.54 32,257,721.06 其中：利息费用 25,822,154.10 33,443,730.44 利息收入 5,452,211.74 4,334,459.37 加：其他收益 69,741,135.46 83,284,962.09 投资收益（损失以"-"号填列） -14,370,446.64 -1,288,863.23 其中：对联营企业和合营企业的投资收益 -14,504,210.38 -15,244,148.07 以摊余成本计量的金融资产终止确认收益 汇兑收益（损失以"-"号填列） 净敞口套期收益（损失以"-"号填列） 公允价值变动收益（损失以"-"号填列） -459,827.92 信用减值损失（损失以"-"号填列） -23,146,737.30 -50,826,479.16 资产减值损失（损失以 ...

Core Insights - The pet economy in China is experiencing significant growth, driven by the changing attitudes of younger consumers who now view pets as family members rather than mere animals [3][5] - The Chinese pet market is projected to exceed 300 billion yuan in 2024, with a year-on-year growth of 7.5%, and is expected to reach 330 billion yuan by 2025 [3] - The animal health market in China ranks second globally and presents substantial growth opportunities, as many needs remain unmet [3][4] Company Insights - Merck, a Fortune 500 company, reported a revenue of $9.3 billion in 2024, providing vaccines, pharmaceuticals, diagnostic products, and professional services for pets and livestock [2] - As of July 16, Merck's market capitalization was approximately $70 billion [2] - Merck has established a research and production base in Suzhou, China, to better meet local demands and strengthen its supply chain [4] Challenges and Opportunities - The global trade environment poses challenges, particularly regarding tariffs, which can increase costs for pet owners and affect the animal health market [4] - Merck is focusing on local production and supply chain strategies to mitigate tariff impacts and has implemented short-term measures like increasing inventory [4][5] - Despite economic uncertainties, pet owners are willing to invest in their pets' health, indicating a resilient market with rising demand for veterinary services and new treatment options [5]

Core Insights - The company reported a revenue of 2.704 billion yuan and a net profit attributable to shareholders of 438 million yuan for the year 2024, with a 20.23% year-on-year growth in pharmaceutical industrial revenue driven by optimized marketing strategies [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 2.704 billion yuan and a net profit of 438 million yuan [1] - The pharmaceutical industrial revenue grew by 20.23% year-on-year due to enhanced marketing model adjustments [1] Group 2: Market Participation and Product Offerings - The company actively participated in national drug procurement projects, securing 14 core specifications in the third batch of national traditional Chinese medicine procurement [1] - A total of 86 products from the company were included in the latest national medical insurance directory, with 35 classified as Category A and 51 as Category B [1] Group 3: Marketing Strategy and Network Development - The company has established a nationwide marketing network covering over 6,000 medical institutions across more than 30 provinces, integrating a full-chain service system from urban public hospitals to retail terminals [3] - The marketing strategy focuses on cardiovascular and respiratory diseases while expanding into pediatric and digestive health markets, utilizing diverse sales channels and marketing strategies to drive growth [2][3] - The company emphasizes a comprehensive marketing approach with a focus on sales capability enhancement across different business units, targeting commercial sales, medical terminal markets, and retail pharmacies [3]

一、报告期内公司主营业务分行业、分产品经营情况 | （一）主营业务分行业情况 | | --- | 单位：元 币种：人民币 | | | | 主营业务分行业情况 | | | | | --- | --- | --- | --- | --- | --- | --- | | 分行业 | 营业收入 | 营业成本 | 毛利率 | 营业收入 比上年增 | 营业成本 比上年增 | 毛利率比 上年增减 | | | | | （%） | | | | | | | | | 减（%） | 减（%） | （%） | | 药品 | 169,362,894.27 | 119,454,668.23 | 29.47 | -29.20 | -6.27 | 减少 17.25 个百分点 | | 医疗器 械 | 13,445,010.16 | 2,341,850.40 | 82.58 | -25.07 | -23.96 | 减 少 0.26 个百分点 | | 商业运 营 | 45,976,063.32 | 11,415,206.57 | 75.17 | -14.26 | -2.42 | 减 少 3.01 个百分点 | | 会展业 务 | 16,473,78 ...

Investment Rating - The investment rating for the company is "Add" and maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, the first quarter of 2025 showed a recovery with revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The company is facing pressure in the pig vaccine segment due to increased competition, while the poultry vaccine and pharmaceutical segments are showing growth. The pet vaccine segment is also emerging as a new growth area, with sales exceeding 46 million yuan in 2024 [5] - The company is implementing marketing strategy adjustments and organizational changes to strengthen cost control and core competitiveness, anticipating a recovery in performance as the pig vaccine market stabilizes and new growth opportunities in pet vaccines arise [6] Financial Summary - The company’s financial performance is projected to improve from 2025 to 2027, with expected earnings per share (EPS) of 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively. The revenue is expected to grow from 1.131 billion yuan in 2025 to 1.259 billion yuan in 2027, with net profit projected to increase from 169 million yuan to 237 million yuan over the same period [7][9]

Investment Rating - The investment rating for the company is "Add" and it is maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, in Q1 2025, the company showed signs of recovery with a revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The performance of different vaccine products varies significantly, with poultry vaccines showing continuous growth, while pig vaccines are under pressure due to increased competition in the swine breeding industry. The company’s revenue from poultry vaccines and antibodies increased by 3.31% and 33.80% respectively in 2024 and Q1 2025, while revenue from pig vaccines decreased by 22.58% and 11.64% respectively [5] - The company is expected to recover as it adjusts its marketing strategy and implements organizational changes, with projected EPS for 2025-2027 being 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively, maintaining an "Add" rating [6] Company Overview - The latest closing price of the company's stock is 13.70 yuan, with a total market capitalization of 4.7 billion yuan. The company has a total share capital of 346 million shares, with a debt-to-asset ratio of 15.2% and a P/E ratio of 50.74 [3][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.043 billion yuan in 2024, a decrease of 16.77% year-on-year, and a net profit attributable to the parent company of 93 million yuan, down 46.82% [5] - In Q1 2025, the company achieved a revenue of 279 million yuan, an increase of 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% [5] - The company is facing short-term pressure in its piglet business due to intensified industry competition, but is focusing on growth in poultry vaccines and pharmaceuticals, as well as increasing sales in ruminant and pet vaccines [5][6] - The company has adjusted its profit forecasts for 2025-2026 downwards and added a forecast for 2027, expecting net profits of 171 million, 207 million, and 249 million yuan for 2025-2027 respectively [5] Financial Summary - The company's revenue for 2025 is estimated at 1.211 billion yuan, with a year-on-year growth of 16.1% [9] - The gross margin for Q1 2025 is reported at 59.71%, a decrease of 4.70 percentage points, while the net margin is 18.99%, an increase of 7.39 percentage points [7] - R&D expenses for 2024 amounted to 106 million yuan, representing 10.17% of total revenue [7] - The company’s earnings per share (EPS) for 2025 is projected to be 0.49 yuan, with a price-to-earnings (P/E) ratio of 27.7 [9]